상세 보기
Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups
- Abdulhaq, Haifaa;
- Townsend, William;
- Ku, Matthew;
- Gregory, Gareth P.;
- Abramson, Jeremy;
- ... Kim, Won-Seog;
- 외 13명
Citations
WEB OF SCIENCE
3- 제목
- Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups
- 저자
- Abdulhaq, Haifaa; Townsend, William; Ku, Matthew; Gregory, Gareth P.; Abramson, Jeremy; Huang, Huiqiang; Zhang, Huilai; Yoon, Dok Hyun; Kim, Won-Seog; Ghesquieres, Herve; Hertzberg, Mark; Zhang, Qing-Yuan; Kesavan, Murali; Mulvihill, Estefania; Kallemeijn, Martine Joanna; Ta, Richard; Choeurng, Voleak; Lundberg, Linda; Fox, Christopher
- 발행일
- 2025-11-03
- 유형
- Meeting Abstract
- 저널명
- Blood
- 권
- 146
- 페이지
- 3743 ~ 3745
- 언어
- ENG
- 출판사
- ELSEVIER
- 발행국가
- 네덜란드
- 분량
- 3 페이지
- ISSN
- E 1528-0020
P 0006-4971